Successful therapy of @entity1457 in adults and @entity1 with @entity369 -vasopressin ( @entity1831 ) has been reported previously. Data on the use of @entity1951 in neonates is limited. This retrospective study reports the effects of AVP-treatment in neonates with @entity2922 -resistant systemic vasodilatation after cardiopulmonary bypass. From March 2003 through December 2005, 172 neonates underwent open-heart surgery, 17 developed vasopressor-resistant @entity551 and were treated with AVP. Thirteen @entity1 had a stage I palliation of single ventricle, two had a Ross-operation and two had an arterial switch operation. All @entity1 received multiple traditional inotropes and vasopressors prior to administration of AVP. AVP was started at median 0.0001 U x kg(-1) x @entity1009 ) (range 0.00005-0.0002) and titrated up to a maximum of median 0.0003 U x kg(-1) x @entity1009 ) (range 0.0001-0.001). AVP led to a significant increase in blood pressure (from 49+/-8 mmHg to 69+/-7 mmHg) and the requirement of traditional vasopressors decreased significantly. No peripheral vasoconstriction or @entity63 was observed. Four of 13 @entity1 , all with single ventricle palliation, died. In two @entity1 @entity204 occurred due to additional complications 6 days after AVP was discontinued. One @entity1 , who was still on AVP, died 42 hours postoperatively after prolonged @entity519 not responding to inhaled @entity842 . One @entity1 arrested on the third postoperative day when AVP was almost weaned. CONCLUSION: In neonates with @entity1457 after cardiopulmonary bypass AVP is a potent agent to increase blood pressure when traditional vasopressors are failing.

XXXX -vasopressin in neonates with @entity1457 after cardiopulmonary bypass.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity1831 :: ('CHEBI:34543', 'Chemical') :: ['AVP'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity1009 :: ('966', 'Gene') :: ['min(-1'] @entity1457 :: ('MESH:D012769', 'Disease') :: ['vasodilatory shock'] @entity1951 :: ('MESH:D014667', 'Chemical') :: ['vasopressin'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxemia'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity2922 :: ('CHEBI:33567', 'Chemical') :: ['catecholamine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension'] @entity369 :: ('CHEBI:29016', 'Chemical') :: ['arginine']
@entity369 :: (CHEBI:29016,Chemical) :: ['Arginine']
